Contact
searchSearch
HMP Global

HEOR

Featured Article

News
Added SGLT2 Inhibitor Therapy of Intermediate/Low Value in Heart Failure With Preserved Ejection Fraction 
03/29/2023
Jolynn Tumolo
Researchers investigated the lifetime cost effectiveness of standard therapy with vs without an SGLT2 inhibitor to reduce the risk of adverse outcomes in patients with heart failure.
Researchers investigated the lifetime cost effectiveness of standard therapy with vs without an SGLT2 inhibitor to reduce the risk of adverse outcomes in patients with heart failure.
Researchers investigated the...
03/29/2023
First Report Managed Care
Headshot of Merle Diamond, MD, Diamond Headache Clinic, on a blue background underneath the PopHealth Perspectives logo.
Podcasts
Migraine's Impact on Productivity, Quality of Life
05/19/2022
Edan Stanley; Maria Asimopoulos
Merle Diamond, MD, AQH, director, Diamond Headache Clinic and inpatient headache unit at Saint Joseph Hospital, offers insight into the prevalence and burden of migraine, as well as risk factors that can cause migraine to progress from...
Merle Diamond, MD, AQH, director, Diamond Headache Clinic and inpatient headache unit at Saint Joseph Hospital, offers insight into the prevalence and burden of migraine, as well as risk factors that can cause migraine to progress from...
Merle Diamond, MD, AQH,...
05/19/2022
First Report Managed Care
Headshot of Gary Owens, MD, on a blue background underneath the PopHealth Perspectives logo.
Podcasts
How Payers Can Use Clinical, Value Comparison Data for Atopic Dermatitis Therapy
09/24/2021
Edan Stanley
Gary Owens, MD, president of Gary Owens Associates, shares his thoughts on the challenges of choosing treatment options for patients with atopic dermatitis, and highlights key takeaways for payers from a recent ICER report which compared the...
Gary Owens, MD, president of Gary Owens Associates, shares his thoughts on the challenges of choosing treatment options for patients with atopic dermatitis, and highlights key takeaways for payers from a recent ICER report which compared the...
Gary Owens, MD, president of...
09/24/2021
First Report Managed Care
News
Screening for Spinal Muscular Atrophy Enhances Nusinersen Cost-Effectiveness
01/22/2021
“Universal newborn screening for spinal muscular atrophy provides improved economic value for payers and patients when nusinersen is available,” wrote researchers from Weill Cornell Medical College and the University of Utah School of...
“Universal newborn screening for spinal muscular atrophy provides improved economic value for payers and patients when nusinersen is available,” wrote researchers from Weill Cornell Medical College and the University of Utah School of...
“Universal newborn screening for...
01/22/2021
First Report Managed Care
News
Cost-Effectiveness of Implantable Loop Recorder Monitoring After Stroke in Line Wth Other Therapies
12/06/2020
For detecting occult atrial fibrillation in patients with cryptogenic stroke, 3-year implantable loop recorder monitoring has a cost per quality-adjusted life-year gained in the range of other publicly funded therapies
For detecting occult atrial fibrillation in patients with cryptogenic stroke, 3-year implantable loop recorder monitoring has a cost per quality-adjusted life-year gained in the range of other publicly funded therapies
For detecting occult atrial...
12/06/2020
First Report Managed Care
Videos
Discussing Treatment Paradigm Shifts, Successful Therapy Options for Atopic Dermatitis
11/13/2020
Vivian Shi, MD, FAAD, associate professor of dermatology, University of Arkansas for Medical Sciences, describes challenges involved with treating atopic dermatitis, highlights the benefits of dupilumab—particularly among pediatric patients,...
Vivian Shi, MD, FAAD, associate professor of dermatology, University of Arkansas for Medical Sciences, describes challenges involved with treating atopic dermatitis, highlights the benefits of dupilumab—particularly among pediatric patients,...
Vivian Shi, MD, FAAD, associate...
11/13/2020
First Report Managed Care
Literature Review
Regulating the Use of CAR-T Therapy Outside of the Drug Paradigm
10/23/2020
Julie Gould
Currently, chimeric antigen receptor T-cell (CAR-T) therapies are regulated as drugs—often leading to higher prices and barriers to access for patients, as well as financial strains for hospitals. However, in a recent insights article in JAMA...
Currently, chimeric antigen receptor T-cell (CAR-T) therapies are regulated as drugs—often leading to higher prices and barriers to access for patients, as well as financial strains for hospitals. However, in a recent insights article in JAMA...
Currently, chimeric antigen...
10/23/2020
First Report Managed Care
Podcasts
Weighing Benefits and Challenges to Effectively Treat Atopic Dermatitis
09/16/2020
Steven Feldman, MD, PhD, Wake Forest University School of Medicine, discusses the real-world effectiveness of dupilumab for the treatment of atopic dermatitis, how this data is relevant for payers, and stresses the importance of studying...
Steven Feldman, MD, PhD, Wake Forest University School of Medicine, discusses the real-world effectiveness of dupilumab for the treatment of atopic dermatitis, how this data is relevant for payers, and stresses the importance of studying...
Steven Feldman, MD, PhD, Wake...
09/16/2020
First Report Managed Care
First Report
HEOR First Report: A Deeper Look at the Benefits of Hemlibra
08/31/2020
Edan Stanley
Karen Powell, PharmD, MS, Pharmacy Solutions Coordinator, Conduent, discusses a recent study in which she and her colleagues measured the cost effectiveness and utilizations rates associated with emicizumab-kxwh treatment for patients with...
Karen Powell, PharmD, MS, Pharmacy Solutions Coordinator, Conduent, discusses a recent study in which she and her colleagues measured the cost effectiveness and utilizations rates associated with emicizumab-kxwh treatment for patients with...
Karen Powell, PharmD, MS,...
08/31/2020
First Report Managed Care
News
Examining the Cost-Effectiveness of DLBCL Treatment
08/27/2020
Because patients with relapsed or refractory diffuse large B-cell lymphoma have limited treatment options and poor prognoses, researchers recently examined the cost-effectiveness of treatments for this patient population.
Because patients with relapsed or refractory diffuse large B-cell lymphoma have limited treatment options and poor prognoses, researchers recently examined the cost-effectiveness of treatments for this patient population.
Because patients with relapsed...
08/27/2020
First Report Managed Care
Podcasts
Discussing Effectiveness, Persistence Rates for Atopic Dermatitis Therapy
08/13/2020
Jonathan Silverberg, MD, PhD, MPH, associate professor of dermatology at The George Washington University School of Medicine and Health Sciences, Washington, DC, offers insight into his real-world data study in which he and his colleagues...
Jonathan Silverberg, MD, PhD, MPH, associate professor of dermatology at The George Washington University School of Medicine and Health Sciences, Washington, DC, offers insight into his real-world data study in which he and his colleagues...
Jonathan Silverberg, MD, PhD,...
08/13/2020
First Report Managed Care

Newsfeed

News
Added SGLT2 Inhibitor Therapy of Intermediate/Low Value in Heart Failure With Preserved Ejection Fraction 
03/29/2023
Jolynn Tumolo
Researchers investigated the lifetime cost effectiveness of standard therapy with vs without an SGLT2 inhibitor to reduce the risk of adverse outcomes in patients with heart failure.
Researchers investigated the lifetime cost effectiveness of standard therapy with vs without an SGLT2 inhibitor to reduce the risk of adverse outcomes in patients with heart failure.
Researchers investigated the...
03/29/2023
First Report Managed Care
News
Cost-Effectiveness of Implantable Loop Recorder Monitoring After Stroke in Line Wth Other Therapies
12/06/2020
For detecting occult atrial fibrillation in patients with cryptogenic stroke, 3-year implantable loop recorder monitoring has a cost per quality-adjusted life-year gained in the range of other publicly funded therapies
For detecting occult atrial fibrillation in patients with cryptogenic stroke, 3-year implantable loop recorder monitoring has a cost per quality-adjusted life-year gained in the range of other publicly funded therapies
For detecting occult atrial...
12/06/2020
First Report Managed Care
Conference Insider
Latanoprostene Bunod Proves Cost-Effective for Primary Open-Angle Glaucoma
11/20/2019
When compared to prostaglandin analogs (PGA), latanoprostene bunod appears to be cost-saving in the treatment of primary open-angle glaucoma, according to data presented at AMCP Nexus 2019. 
When compared to prostaglandin analogs (PGA), latanoprostene bunod appears to be cost-saving in the treatment of primary open-angle glaucoma, according to data presented at AMCP Nexus 2019. 
When compared to prostaglandin...
11/20/2019
First Report Managed Care
Behind the Bill
CMS Expands Oversight and Competition Among Organ Procurement Organizations
11/06/2026
Grace Taylor, MS, MA
New Centers for Medicare & Medicaid Services (CMS) requirements address organ procurement safety, performance measurement, and service-area transitions, with implications for transplant access and care coordination.
New Centers for Medicare & Medicaid Services (CMS) requirements address organ procurement safety, performance measurement, and service-area transitions, with implications for transplant access and care coordination.
New Centers for Medicare &...
11/06/2026
First Report Managed Care
News
MASH Treatment Model Projects Significant Economic Wastage With Low Semaglutide Persistence
11/06/2026
Rebecca Amrick
A study presented at AASLD TLM 2026 found that low adherence to optimal-dose semaglutide among patients with metabolic dysfunction-associated steatohepatitis (MASH) was projected to contribute to significant excess medical and pharmacy costs...
A study presented at AASLD TLM 2026 found that low adherence to optimal-dose semaglutide among patients with metabolic dysfunction-associated steatohepatitis (MASH) was projected to contribute to significant excess medical and pharmacy costs...
A study presented at AASLD TLM...
11/06/2026
First Report Managed Care
News
MASH Disease Progression Associated With Increased Economic Burden Among Medicare Beneficiaries
11/04/2026
Rebecca Amrick
A study of Medicare fee-for-service beneficiaries found that those with metabolic dysfunction-associated steatohepatitis (MASH) had higher health care utilization rates and medical costs compared to those without MASH, with the greatest...
A study of Medicare fee-for-service beneficiaries found that those with metabolic dysfunction-associated steatohepatitis (MASH) had higher health care utilization rates and medical costs compared to those without MASH, with the greatest...
A study of Medicare...
11/04/2026
First Report Managed Care
News
Real-World Evidence Highlights Broader Benefits of Omalizumab for Food Allergy Management
11/03/2026
Hannah Musick
A narrative review of real-world evidence suggests that omalizumab may improve food allergy management beyond preventing allergic reactions, with potential benefits for dietary flexibility, quality of life, and patients with complex allergic...
A narrative review of real-world evidence suggests that omalizumab may improve food allergy management beyond preventing allergic reactions, with potential benefits for dietary flexibility, quality of life, and patients with complex allergic...
A narrative review of real-world...
11/03/2026
First Report Managed Care
News
Direct Patient and Caregiver Engagement in Prior Authorization Linked to Care Delays
11/03/2026
Rebecca Amrick
Researchers found that direct patient and caregiver involvement in prior authorization procedures was associated with delayed or suboptimal care, highlighting the need for policy reform to reduce administrative burdens and improve access to...
Researchers found that direct patient and caregiver involvement in prior authorization procedures was associated with delayed or suboptimal care, highlighting the need for policy reform to reduce administrative burdens and improve access to...
Researchers found that direct...
11/03/2026
First Report Managed Care
Behind the Bill
HHS HTI-5 Final Rule Cuts Health IT Requirements With $1.5 Billion in Projected Savings
10/30/2026
Grace Taylor, MS, MA
The US Department of Health and Human Services’ (HHS) Health Data, Technology, and Interoperability (HTI-5) final rule reduces health IT certification requirements and projects substantial regulatory savings while leaving proposed...
The US Department of Health and Human Services’ (HHS) Health Data, Technology, and Interoperability (HTI-5) final rule reduces health IT certification requirements and projects substantial regulatory savings while leaving proposed...
The US Department of Health and...
10/30/2026
First Report Managed Care
News
Suboptimal TKI Adherence Across Payer Types Among Patients With CML
10/30/2026
Rebecca Amrick
A comparison of insurance types showed that tyrosine kinase inhibitor (TKI) approval for patients with chronic myeloid leukemia (CML) was higher among Medicare and Medicaid beneficiaries, but treatment adherence remained suboptimal across...
A comparison of insurance types showed that tyrosine kinase inhibitor (TKI) approval for patients with chronic myeloid leukemia (CML) was higher among Medicare and Medicaid beneficiaries, but treatment adherence remained suboptimal across...
A comparison of insurance types...
10/30/2026
First Report Managed Care
News
Real-World Study Reveals Shifting Treatment Patterns and Persistent Unmet Needs in DLBCL
10/29/2026
Hannah Musick
A real-world US study found that novel therapies are increasingly replacing conventional treatments for diffuse large B-cell lymphoma (DLBCL), although declining survival outcomes across successive lines of therapy and substantial variation...
A real-world US study found that novel therapies are increasingly replacing conventional treatments for diffuse large B-cell lymphoma (DLBCL), although declining survival outcomes across successive lines of therapy and substantial variation...
A real-world US study found that...
10/29/2026
First Report Managed Care
News
Inadequate Hematocrit Control in Polycythemia Vera Linked to High Health Care Burden
10/29/2026
Grace Taylor, MS, MA
A US claims study found that patients with polycythemia vera frequently experienced inadequate hematocrit control despite treatment, with thromboembolic events contributing to substantial health care costs.
A US claims study found that patients with polycythemia vera frequently experienced inadequate hematocrit control despite treatment, with thromboembolic events contributing to substantial health care costs.
A US claims study found that...
10/29/2026
First Report Managed Care
News
MA Associated With Less Expensive Cancer Therapies but Similar Treatment Utilization Compared to TM
10/28/2026
Rebecca Amrick
Researchers found that while Medicare Advantage (MA) is associated with lower-cost cancer treatments, beneficiaries had a similar likelihood of initiating optimal treatments for cancer type as those enrolled in traditional Medicare (TM).
Researchers found that while Medicare Advantage (MA) is associated with lower-cost cancer treatments, beneficiaries had a similar likelihood of initiating optimal treatments for cancer type as those enrolled in traditional Medicare (TM).
Researchers found that while...
10/28/2026
First Report Managed Care

Literature Review

Literature Review
Improved Therapy Options for Patients with Neuroendocrine Tumors
02/23/2019
Kara Rosania, MS
Neuroendocrine tumors (NETs) are thought to arise from cells throughout the diffuse endocrine system. According to a report published in JAMA Oncology, the incidence and prevalence of NETS are steadily rising, though for reasons not well...
Neuroendocrine tumors (NETs) are thought to arise from cells throughout the diffuse endocrine system. According to a report published in JAMA Oncology, the incidence and prevalence of NETS are steadily rising, though for reasons not well...
Neuroendocrine tumors (NETs) are...
02/23/2019
First Report Managed Care
Literature Review
Promising Outcomes for SER-109: A New Approach to Managing Recurrent CDI
10/23/2023
Danielle Sposato
Not only does SER-109 effectively treat CDI, but results show that it can even reduce recurrence. A major benefit when it comes to associated health care costs for patients.
Not only does SER-109 effectively treat CDI, but results show that it can even reduce recurrence. A major benefit when it comes to associated health care costs for patients.
Not only does SER-109...
10/23/2023
First Report Managed Care
Literature Review
Comparing IL-6 Inhibitors and Glucocorticoids in Treating PMR: SAPHYR Trial Results
10/16/2023
Danielle Sposato
The SAPHYR trial has provided researchers with valuable insights into alternative treatment options for PMR due to its larger patient population. The effectiveness of sarilumab and the achieved rates of remission offer promise for enhancing...
The SAPHYR trial has provided researchers with valuable insights into alternative treatment options for PMR due to its larger patient population. The effectiveness of sarilumab and the achieved rates of remission offer promise for enhancing...
The SAPHYR trial has provided...
10/16/2023
First Report Managed Care
Literature Review
A Look at the Impact, Prevalence of Demodex Blepharitis
12/06/2022
Edan Stanley
This article explores the incidence, prevalence, and management of Demodex Blepharitis.
This article explores the incidence, prevalence, and management of Demodex Blepharitis.
This article explores the...
12/06/2022
First Report Managed Care
Literature Review
Anti-CD38 Monoclonal Antibody for Multiple Myeloma: A Review of Clinical Trials
11/29/2022
Maria Asimopoulos
Several ongoing and upcoming clinical trials are testing the efficacy and safety of a monoclonal antibody in combination with other therapies for multiple myeloma.
Several ongoing and upcoming clinical trials are testing the efficacy and safety of a monoclonal antibody in combination with other therapies for multiple myeloma.
Several ongoing and upcoming...
11/29/2022
First Report Managed Care
Literature Review
Isatuximab Demonstrates Significant PFS Among Patients With Multiple Myeloma
09/23/2022
Edan Stanley
This literature review explores the latest progression-free survival data for a multiple myeloma therapy option.
This literature review explores the latest progression-free survival data for a multiple myeloma therapy option.
This literature review explores...
09/23/2022
First Report Managed Care
Literature Review
Bladder Cancers: What is Low-Grade Upper Tract Urothelial Carcinoma?
09/16/2022
Edan Stanley
This literature review explores key data related to the epidemiology, clinical presentation, and treatment considerations for patients with low-grade upper tract urothelial carcinoma.
This literature review explores key data related to the epidemiology, clinical presentation, and treatment considerations for patients with low-grade upper tract urothelial carcinoma.
This literature review explores...
09/16/2022
First Report Managed Care
Literature Review
Examining 177Lu-PSMA-617 as a Treatment for Metastatic Castration-resistant Prostate Cancer
09/16/2021
Jeff Craven
In this literature review, we explore the data from the phase 3 VISION trial recently presented at the 2021 virtual annual meeting of the American Society of Clinical Oncology and published in the New England Journal of Medicine, examining...
In this literature review, we explore the data from the phase 3 VISION trial recently presented at the 2021 virtual annual meeting of the American Society of Clinical Oncology and published in the New England Journal of Medicine, examining...
In this literature review, we...
09/16/2021
First Report Managed Care
Literature Review
Examining Benefits of Cannabidiol for Patients With Seizures
08/12/2021
Edan Stanley
For the purpose of this literature review, we examine the latest data presented at the American Academy of Neurology’s (AAN) 2021 Virtual Annual Meeting regarding the use of CBD for patients with seizure disorders including TSC.  
For the purpose of this literature review, we examine the latest data presented at the American Academy of Neurology’s (AAN) 2021 Virtual Annual Meeting regarding the use of CBD for patients with seizure disorders including TSC.  
For the purpose of this...
08/12/2021
First Report Managed Care
Literature Review
Examining Dry Eye Disease Flare Treatments
05/28/2021
Edan Stanley
With a newly proposed and easily applicable definition for dry eye disease, researchers believe the condition can be diagnosed with more consistency as well as inform future trials and research. 
With a newly proposed and easily applicable definition for dry eye disease, researchers believe the condition can be diagnosed with more consistency as well as inform future trials and research. 
With a newly proposed and easily...
05/28/2021
First Report Managed Care
Literature Review
Examining Lasmiditan for the Acute Treatment of Migraine Compared With Triptans
02/12/2021
Edan Stanley
Per the American Migraine foundation, oral and intranasal triptan therapy has proven consistently effective when used to treat migraine earlier in the attack; however, triptan therapy is not effective for all patients with migraine and cannot...
Per the American Migraine foundation, oral and intranasal triptan therapy has proven consistently effective when used to treat migraine earlier in the attack; however, triptan therapy is not effective for all patients with migraine and cannot...
Per the American Migraine...
02/12/2021
First Report Managed Care

Literature Review

Literature Review
Improved Therapy Options for Patients with Neuroendocrine Tumors
02/23/2019
Kara Rosania, MS
Neuroendocrine tumors (NETs) are thought to arise from cells throughout the diffuse endocrine system. According to a report published in JAMA Oncology, the incidence and prevalence of NETS are steadily rising, though for reasons not well...
Neuroendocrine tumors (NETs) are thought to arise from cells throughout the diffuse endocrine system. According to a report published in JAMA Oncology, the incidence and prevalence of NETS are steadily rising, though for reasons not well...
Neuroendocrine tumors (NETs) are...
02/23/2019
First Report Managed Care
Literature Review
Promising Outcomes for SER-109: A New Approach to Managing Recurrent CDI
10/23/2023
Danielle Sposato
Not only does SER-109 effectively treat CDI, but results show that it can even reduce recurrence. A major benefit when it comes to associated health care costs for patients.
Not only does SER-109 effectively treat CDI, but results show that it can even reduce recurrence. A major benefit when it comes to associated health care costs for patients.
Not only does SER-109...
10/23/2023
First Report Managed Care
Literature Review
Comparing IL-6 Inhibitors and Glucocorticoids in Treating PMR: SAPHYR Trial Results
10/16/2023
Danielle Sposato
The SAPHYR trial has provided researchers with valuable insights into alternative treatment options for PMR due to its larger patient population. The effectiveness of sarilumab and the achieved rates of remission offer promise for enhancing...
The SAPHYR trial has provided researchers with valuable insights into alternative treatment options for PMR due to its larger patient population. The effectiveness of sarilumab and the achieved rates of remission offer promise for enhancing...
The SAPHYR trial has provided...
10/16/2023
First Report Managed Care
Literature Review
A Look at the Impact, Prevalence of Demodex Blepharitis
12/06/2022
Edan Stanley
This article explores the incidence, prevalence, and management of Demodex Blepharitis.
This article explores the incidence, prevalence, and management of Demodex Blepharitis.
This article explores the...
12/06/2022
First Report Managed Care
Literature Review
Anti-CD38 Monoclonal Antibody for Multiple Myeloma: A Review of Clinical Trials
11/29/2022
Maria Asimopoulos
Several ongoing and upcoming clinical trials are testing the efficacy and safety of a monoclonal antibody in combination with other therapies for multiple myeloma.
Several ongoing and upcoming clinical trials are testing the efficacy and safety of a monoclonal antibody in combination with other therapies for multiple myeloma.
Several ongoing and upcoming...
11/29/2022
First Report Managed Care
Literature Review
Isatuximab Demonstrates Significant PFS Among Patients With Multiple Myeloma
09/23/2022
Edan Stanley
This literature review explores the latest progression-free survival data for a multiple myeloma therapy option.
This literature review explores the latest progression-free survival data for a multiple myeloma therapy option.
This literature review explores...
09/23/2022
First Report Managed Care
Literature Review
Bladder Cancers: What is Low-Grade Upper Tract Urothelial Carcinoma?
09/16/2022
Edan Stanley
This literature review explores key data related to the epidemiology, clinical presentation, and treatment considerations for patients with low-grade upper tract urothelial carcinoma.
This literature review explores key data related to the epidemiology, clinical presentation, and treatment considerations for patients with low-grade upper tract urothelial carcinoma.
This literature review explores...
09/16/2022
First Report Managed Care
Literature Review
Examining 177Lu-PSMA-617 as a Treatment for Metastatic Castration-resistant Prostate Cancer
09/16/2021
Jeff Craven
In this literature review, we explore the data from the phase 3 VISION trial recently presented at the 2021 virtual annual meeting of the American Society of Clinical Oncology and published in the New England Journal of Medicine, examining...
In this literature review, we explore the data from the phase 3 VISION trial recently presented at the 2021 virtual annual meeting of the American Society of Clinical Oncology and published in the New England Journal of Medicine, examining...
In this literature review, we...
09/16/2021
First Report Managed Care
Literature Review
Examining Benefits of Cannabidiol for Patients With Seizures
08/12/2021
Edan Stanley
For the purpose of this literature review, we examine the latest data presented at the American Academy of Neurology’s (AAN) 2021 Virtual Annual Meeting regarding the use of CBD for patients with seizure disorders including TSC.  
For the purpose of this literature review, we examine the latest data presented at the American Academy of Neurology’s (AAN) 2021 Virtual Annual Meeting regarding the use of CBD for patients with seizure disorders including TSC.  
For the purpose of this...
08/12/2021
First Report Managed Care
Literature Review
Examining Dry Eye Disease Flare Treatments
05/28/2021
Edan Stanley
With a newly proposed and easily applicable definition for dry eye disease, researchers believe the condition can be diagnosed with more consistency as well as inform future trials and research. 
With a newly proposed and easily applicable definition for dry eye disease, researchers believe the condition can be diagnosed with more consistency as well as inform future trials and research. 
With a newly proposed and easily...
05/28/2021
First Report Managed Care
Literature Review
Examining Lasmiditan for the Acute Treatment of Migraine Compared With Triptans
02/12/2021
Edan Stanley
Per the American Migraine foundation, oral and intranasal triptan therapy has proven consistently effective when used to treat migraine earlier in the attack; however, triptan therapy is not effective for all patients with migraine and cannot...
Per the American Migraine foundation, oral and intranasal triptan therapy has proven consistently effective when used to treat migraine earlier in the attack; however, triptan therapy is not effective for all patients with migraine and cannot...
Per the American Migraine...
02/12/2021
First Report Managed Care

First Report

First Report
HEOR First Report: A Deeper Look at the Benefits of Hemlibra
08/31/2020
Edan Stanley
Karen Powell, PharmD, MS, Pharmacy Solutions Coordinator, Conduent, discusses a recent study in which she and her colleagues measured the cost effectiveness and utilizations rates associated with emicizumab-kxwh treatment for patients with...
Karen Powell, PharmD, MS, Pharmacy Solutions Coordinator, Conduent, discusses a recent study in which she and her colleagues measured the cost effectiveness and utilizations rates associated with emicizumab-kxwh treatment for patients with...
Karen Powell, PharmD, MS,...
08/31/2020
First Report Managed Care
First Report
Vibegron Proves Effective as Oral Therapy for Patients With Overactive Bladder
04/12/2021
Edan Stanley
While OAB is not associated with high mortality rates, its effects on quality of life and overall burden can be stressful to patients and diagnosis/treatment is often delayed due to patients’ lack of understanding of available treatments.
While OAB is not associated with high mortality rates, its effects on quality of life and overall burden can be stressful to patients and diagnosis/treatment is often delayed due to patients’ lack of understanding of available treatments.
While OAB is not associated with...
04/12/2021
First Report Managed Care
First Report
HEOR First Report: A Deeper Look at the Benefits of Hemlibra
08/31/2020
Edan Stanley
Karen Powell, PharmD, MS, Pharmacy Solutions Coordinator, Conduent, discusses a recent study in which she and her colleagues measured the cost effectiveness and utilizations rates associated with emicizumab-kxwh treatment for patients with...
Karen Powell, PharmD, MS, Pharmacy Solutions Coordinator, Conduent, discusses a recent study in which she and her colleagues measured the cost effectiveness and utilizations rates associated with emicizumab-kxwh treatment for patients with...
Karen Powell, PharmD, MS,...
08/31/2020
First Report Managed Care
First Report
Decreased Medication, Utilization Costs Identified With Emicizumab-kxwh Therapy for Hemophilia
08/31/2020
Edan Stanley
Emicizumab-kxwh, which was approved by the FDA in November 2017 to prevent or reduce the frequency of bleeding episodes in patients with hemophilia (HEM) A and FVIII inhibitors, was found to be associated with decreased medication and...
Emicizumab-kxwh, which was approved by the FDA in November 2017 to prevent or reduce the frequency of bleeding episodes in patients with hemophilia (HEM) A and FVIII inhibitors, was found to be associated with decreased medication and...
Emicizumab-kxwh, which was...
08/31/2020
First Report Managed Care

HMP Global Products

Events

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2026 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Terms of Use